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The importance of low frequency and rare variation in complex disease genetics
is difficult to estimate in patient populations. Genome-wide association studies are
therefore, underpowered to detect rare variation. We have used a combined approach
of genome-wide-based imputation with a highly stringent sequence kernel association
(SKAT) test and a case-control burden test. We identified 98 candidate genes containing
rare variation that in aggregate show association with SLE many of which have
recognized immunological function, but also function and expression related to relevant
tissues such as the joints, skin, blood or central nervous system. In addition we also find
that there is a significant enrichment of genes annotated for disease-causing mutations in
the OMIM database, suggesting that in complex diseases such as SLE, such mutations
may be involved in subtle or combined phenotypes or could accelerate specific organ
abnormalities found in the disease. We here provide an important resource of candidate
genes for SLE.
Keywords: SLE, systemic lupus erythematosus, imputated rare variation, GWAS—genome-wide association study,
sequence kernel association test, aggregated case-control enrichment
INTRODUCTION
Genome-wide association studies have been designed primarily to capture common variation and
so far some 10,000 common genetic variants have been robustly associated with a wide range of
complex diseases (1). Therefore, this methodology is underpowered to detect the effects of rare
variants. There has been much debate as to the role of rare genetic variation on complex traits
(2–4) and how rare variant studies complement GWASs (5). It is now accepted that rare variants
located in different genes could in fact play a more important role in disease susceptibility than
common variants (4). The challenge arises in measuring and statistically analyzing rare variation. It
would be very unexpected to find rare variants that could have substantial effect sizes and therefore
high penetrance contributing to complex traits, being more likely to have mutations with modest
effects. For small effect sizes association testing may require composite tests of overall “mutational
load,” pooling rare variants for analysis by addressing the question: do rare variants increase or
decrease disease risk? (6). In-depth whole-genome sequencing is themost comprehensive approach
for measuring rare and common variation in both coding and non-coding regions. However,
nowadays, its application is limited by the costs and various computational challenges, especially
for large-scale cohorts. Whole-exome sequencing is a cost-effective alternative, however one of its
obvious drawback is the absence of variants in non-coding regions, whichmay be especially relevant
in the context of complex disease genetics. Genotype imputation is likely to remain a valuable tool.
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At this point an interesting cost and a computationally effective
alternative would be to combine genotype imputation with
targeted sequencing in a gene-centered strategy. For dense
genotyping arrays, imputation is able to predict nearly all missing
common variation with high accuracy, but as the variant minor
allele frequency (MAF) decreases, so does the accuracy of
imputation, depending mainly on the size of the reference panel
and the ancestry of the imputed samples, with the best efficiencies
in European cohorts, mainly due to the sufficiently large size of
the European reference panels (7–13).
We have previously tested the overall effect of imputed
rare variation on particular genes in systemic autoimmunity
(14). Recently, we have implemented and successfully applied a
method based on genotype imputation of rare variation, on a set
of genes detected by exome sequencing as possible candidates for
association to systemic lupus erythematosus (SLE) by mutation
in members of Icelandic SLE-multicase families (15).
In the present work the method has been brought to the
genome level to scan for association of protein coding genes
with SLE by rare variation in the European ancestry population.
We executed stringent imputation in a densely genotyped set for
analyzing association with SLE in a sample from the European
population selecting the protein coding genes of the genome and
then applying tests to detect those that significantly associated
with the disease by rare-variation. This procedure provided a
set of 98 genes as good candidates for association with SLE by
mutation. Many of these genes showed immunological related
functions or effects on other organs or tissues affected by
the pathology, such as joints, skin, central nervous system or
blood and some were involved in human energy metabolism
and more specifically as part of the respiratory chain. Such a
diversity of functions is to be expected because of the phenotypic
heterogeneity of a complex disease as SLE.
MATERIALS AND METHODS
Genome-Wide Association Analysis
We used GWAS data from 5,478 individuals of European
ancestry including 4254 SLE patients and 1,224 controls
genotyped using the Illumina HumanOmni1_Quad_v1-0_B
chip. In order to increase the number of controls, additional
data from European subjects were obtained from the dbGaP
database (http://www.ncbi.nlm.nih.gov/gap) including the
DCEG Imputation Reference Dataset (phs000396.v1.p1)
with 1,175 individuals representing general population, and
controls subjects from two case-control studies: 1,047 from
the High Density SNP Association Analysis of Melanoma
(phs000187.v1.p1) and 903 from GENIE UK-ROI Diabetic
Nephropathy GWAS (phs000389.v1.p1). Note that only control
from both case-control studies were included in our analysis.
In total, the initial dataset consisted of 4,254 SLE patients and
4,349 controls.
In order to obtain a quality-controlled working dataset
satisfying current state-of-the-art criteria for association studies,
data filtering was conducted using PLINK v1.07 1 (16) applying
the following criteria: minimum total call rate per sample of 90%,
minimum call rate per marker of 98%, minor allele frequency
(MAF) threshold of 1%, Hardy-Weinberg Equilibrium (HWE)
p-value for cases and controls at a minimum of 0.0001, and in
addition at 0.01 only for controls, and finally a cutoff p-value
of 0.00001 for differential missingness in, the software REAP
was used (17) applying a kinship coefficient threshold <0.055.
To correct for stratification, principal component analysis (PCA)
was performed with smartpca, EIGENSOFT 4.0 beta package 2
(18). To confirm the European ancestry we ran a PCA with the
set of independent markers (r2 < 0.1) that maximized differences
in allelic frequencies between the four main 1000 Genomes
subpopulations (EUR, AFR, AMR, and ASN). No samples were
detected as “non-European” (Supplemental Figure 1). Next, the
PCA was performed with the set of r2 < 0.1, that maximized
differences in the allelic frequencies in 1000 Genomes EUR
subpopulations (CEU, GBR, IBS, TSI, and FIN) and two
additional subpopulations from our sample dataset, Greek
and Turkish (GRK and TUR) representing the south-eastern
European ancestry. The resulting PCs perfectly classified the
individuals from reference populations by their geographical
origin (Supplemental Figure 2). This last set of PCs was used for
correcting for genetic stratification in the case-control association
analysis (Supplemental Figure 3). This resulted in a λGC = 1.05
using the first 10 principal components. The final data set used for
association analysis consisted of 4,212 cases and 4,065 controls.
Imputation
Release 19 (GRCh37.p13) was used as reference (https://
www.encodeproject.org/files/gencode.v19.annotation/). Of
19,430 sequences annotated as “protein coding” in the
gencode.v19.annotation.gtf file, 15,763 included in the final
QC-filtered genotyping data set became our imputation working
gene list. Each protein-coding gene region was extended 500,000
additional base pairs upstream and downstream, respectively,
as it is known that large buffers may improve accuracy for
low-frequency variants during imputation. Markers within
each extended region were extracted from the GWAS data
for imputation with IMPUTE2 (19) using the 1000 Genomes
Project as reference panel. Specifically, we used 1000 Genomes
Phase 3, b37 (October 2014), as these haplotypes have lower
genotype discordance and improved imputation performance
into downstream GWAS samples, especially for low frequency
variants (20, 21). Genome-Wide Association Analysis of Imputed
Rare Variants in complex diseases has been previously used as
a gene-centered approach (7). In this paper imputation into a
GWAS scaffold using the WTCCC European analysis cohort
explicitly showed substantial gains in power to detect rare variant
association within the gene where the extent of the increase in
power depends crucially on the number of individuals in the
reference panel. Therefore, power gains obtained from 500 to
4,000 samples in the reference panel were not as great as from
120 to 500 samples. Based on this, and for the objective of our
study we considered as adequate the 2,504 samples present in
the 1000 Genomes phase 3 reference panel (2014 release, http://
mathgen.stats.ox.ac.uk/impute/1000GP_Phase3/) of which 503
are of European descent. Prior to imputation, each GWAS gene
extended region was phased with SHAPEIT using the 1000
Genomes EUR subpopulation as reference (http://www.shapeit.
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fr/). A restrictive QC-filter was applied on the imputed genotypes
(SNP genotyping rate ≥ 99%, sample genotyping rate ≥ 95%)
without restriction of allele frequencies, in order to include both
rare and low frequency variants. To ensure a highly reliable
imputation, a conservative IMPUTE info_value threshold of ≥
0.75 for each marker were applied as imputation quality score.
Functional Annotation of Genetic Variants
Annotation of analyzed genetic variants in their different
functional categories was carried out using ANNOVAR (22).
Gene Case-Control Association Analysis
by Rare Variation
While there is no universally accepted definition of “rare variant,”
and a minor allele frequency (MAF) of 1% is the conventional
definition of polymorphism, then a MAF < 1% would be
understood as “rare variation.” We tested whether any of the
N genes in the human genome had statistical evidence of
association with SLE in the general European population due
to the combined effect of all rare variation within each gene
(MAF < 1%). Each gene was analyzed using two procedures:
the sequence kernel association (SKAT) test (20, 21) and a case-
control burden test by adjusting a logistic regression model
with a “transformed” “genetic variable” equals to the sum of
minor frequency alleles for all markers below the (<1%) in
the tested gene in each i individual (7). To note that in such
case-control burden test, a result statistically significant indicates
that the overall effect of rare variation on the gene goes in the
same direction being either of risk (aggregate odd ratio > 1) or
alternatively protective (aggregate odd ratio < 1). This feature of
case-control burden analysis helps to interpret the effect of rare
variation on the phenotype. In addition, running two association
procedures, SKAT
⋂
case-control burden test would reduce the
rate of false positives. Thus, we will consider as true positives
those genes with significant association test for both procedures,
SKAT and case-control burden test. However, in association
tests that simultaneously include several markers, one effect of
linkage disequilibrium (LD) between these markers could be
collinearity. We have addressed the LD issue running the tests
with a set of independent markers by applying a very restrictive
LD threshold of r2 < 0.1. It could be argued that association
signals would be lost by applying such a strict threshold of r2
but even so, if the signal remains it supports it as “true positive”
(15). Supplemental Figure 4 summarizes the study workflow.
Correcting for Stratification in Rare Variant
Association Analysis
We verified that the set of Principal Components computed
with common variation was able to correct stratification for rare
variant association analysis in our sample (15). To be as stringent
as possible, the 10 first principal components (PC’s) and genomic
control (GC) were used to correct for stratification in both tests.
For case-control burden 10 PC’s corrected tests, the genomic
inflation factor (λGC) was equal to 1.11 and for SKAT 10 PC’s
corrected tests it was equal to 1.24. These λGC values were used
for correction of the resulting inflation on each type of association
test (GC correction = Statistic 10PC′c_corrected/ λGC). When no
PC’s correction was used, the λGC for case-control burden tests
was equal to 1.44 and 2.97 for SKAT. Thus, the 10 PC’s correction
reduced the inflation by 33% in the case-control burden tests, and
in 174% in the SKAT tests.
Correcting for Multiple Testing in Gene
Case-Control Association Analysis of Rare
Variation
Regarding the question of correcting for multiple testing in gene
association by rare variants, a genomic association threshold
of 106 is accepted (equivalent to Bonferroni correction for
19,000–20,000 protein encoding genes in the genome). It is
also accepted that Bonferroni, although mathematically right
would be very penalizing for biological data, therefore we opted
for techniques based on permutation processes. Our multi-test
correction procedure brings together the genotypes of all rare
variants in all tested genes as columns into a single table. For each
gene a number of markers equal to that of the gene was randomly
extracted from this table and its association test calculated. By
repeating the procedure for N times an empirical corrected P-
value was calculated for each tested gene. It can be argued
that when randomization is done, LD relations are abrogated
affecting the empirical P-values computation in random tests,
but this problem did not affect our multi-testing correction
procedure since we use a working set of independent markers
(r2 < 0.1) (15).
Enrichment in OMIM Annotations in the
“Result-List” of Genes Associated to SLE
by Rare Variation
Taking into account that pleiotropic effects on human complex
traits was widespread (23), it would be expected that in a list
of genes significantly enriched in rare variation there would
also be an enrichment of diseases caused by mutations. To
test this, we used three data sets. First, we downloaded the
OMIM database (http://www.omim.org/downloads/; updated:
March 23, 2015), and employed it to build a ‘gene-disease’ table
with its 20,707 records (“gene-disease” pairs); second, the list of
all GWAS imputed protein-coding genes in our final dataset;
and thirdly, the list of N genes resulting as candidates to be
SLE-associated from our rare variants association analysis. Then
if our “result-list” of N associated genes provided annotations
for X OMIM diseases, the procedure for testing enrichment in
OMIM annotations was to randomly select a set of N genes
from the list of GWAS imputed protein-coding genes, and count
how many of them appeared on the OMIM “gene-disease” table.
This procedure was repeated 1,000 times. The average number of
OMIMdisease and its standard deviation was calculated and then




A total of 13,956 genes passed the QC filter of the imputation
process, summing a set of 5,305,811 markers, 2,595,206 variants
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with MAF > 1% (48.93%), and 2,709,605 variants (mutations)
with MAF < 1% (51.07%). A set of 1,549,436 independent
markers was obtained by applying a threshold of r2 < 0.1. As
expected, rare variation was much less affected by the linkage
disequilibrium than common variation, which resulted in 87,853
variants with MAF > 1% (5.56%) and 1,491,583 variants with
MAF <1% (94.44%) (Figure 1).
A working set of 1,306,324 independent (r2 < 0.1) rare
variants (MAF < 0.1) was used to test genes for case-
control association to the SLE phenotype (185,219 were non-
polymorphic). The reliability of these tests depends on the
accuracy of the imputation. When analyzing reliability of
imputation in rare variants 3 intervals are usually differentiated:
“singletons,” “very rare” variation and “rare” variation (4, 24). It
is known that as the variant MAF decreases, so does the accuracy
of imputation, improving with the size of the reference panel,
and singletons, meaning that the minor allele is observed only in
one chromosome, are not reliably imputed under any conditions.
In our data set, 189,893 (14.5%) variants were singletons (in the
8,277 individuals sample this means a MAF = 0.006%) and if an
FIGURE 1 | After QC filtering, imputation provided a set of 5,305,811
markers: 2,595,206 with MAF > 1% (48.93%) and 2,709,605 with MAF < 1%
(51.07%). A set of 1,549,436 independent markers was obtained by applying
a threshold of r² < 0.1. Rare variation was less affected by the linkage
disequilibrium than common variation, which resulted in 87,853 variants with
MAF > 1% (5.56%) and 1,491,583 variants with MAF < 1% (94.44%). This
last set of 1,491,583 independent rare-variants constituted our working set.
TABLE 1 | Number of independent rare variants vs. sum of minor alleles.
Number of variants Number of minor alleles
Singletons 189,893 (14.5%) 189,893 (0.64%)
MAF<0.01% 676,621 (51.8%) 4,671,537 (16.04%)
0.01% > MAF ≤ 1% 439,810 (33.7%) 24,266,676 (83.33%)
1,306,324 (100%) 29,128,106 (100%)
Rare variation was classified into 3 categories by their minor allele frequencies (MAFs):
(1) singletons that in the 8,277 individuals sample means a MAF = 0.006%, (2)
“very rare-variants,” 0.006% <MAF< 0.1%, (3) and rare variation in a “strict sense,”
0.1% < MAF≤ 1%.
additional threshold of MAF < 0.1% to distinguish rare variant
from a category of “very” rare variant was applied, then 676,621
(51.8%) variants were classified as very rare-variants, while
439,810 (33.7%) had MAF between 0.1 and 1%. These results
suggested that imputed genotype data used in the association
analysis could be unreliable because of the predominance of
markers belonging to the categories of very rare variants and
singletons over the most reliable imputation category of rare
variation, 0.1 < MAF ≤ 1%. However, in tests based on the
combined effect of variants, the main factor is not the number
of markers aggregated but more importantly the count of alleles
of minor frequency in the sample of analyzed individuals. Thus,
in our 8,277 individuals dataset the 3 categories of rare variation
sum up 29,128,106 minor alleles. Singletons represented 14.5%
of rare variation but only 0.65% of minor alleles. The 51.8% of
the markers included in the very rare variation category add up
to 4,671,537 minor frequency alleles, that is, 16.04%; while the
remaining markers, sum up to 24,266,676 of minor frequency
alleles, which represented the 83.33%, resulting in a 5 times
greater ratio of “0.1%<MAF ≤ 1%” variation compared to the
sum of the other two categories (Table 1, Figure 2). Therefore,
despite its lower proportion, the expected effect of rare variation
on the aggregate test would be greater than that of the “very
rare” variation and singletons providing a higher reliability to
the analysis.
Note that the proportions of the different functional categories
in the rare variation (MAF < 1% with and without r² filtering
was similar (Table 2, Figure 3), being the intronic the most
abundant category, 85% of the total, while the exonic rare
variants represented only 2%, of which more than 98% were
synonymous (Figure 4).
Rare-Variant Association Gene-Centered
Analysis, and OMIM Annotation
Enrichment
Under these conditions a set of 281 genes showed SKAT test
with Genomic Control and multi-testing corrected P < 0.05
(Supplemental Table 1). Noted that 441 genes also presented
Genomic Control and multi-testing corrected significant tests
for enrichment in rare variation (Supplemental Table 2). When
the OMIM annotation enrichment analysis were executed, the
list of SKAT associated genes was significantly enriched with
119 OMIM diseases (Supplemental Table 3) instead of the 81
expected at random, which gave a value of P = 3E-03. Of
these 281 genes, 139 were enriched in mutations in cases vs.
controls and the remaining 142 were depleted. Note that the
list of 139 genes enriched in mutations had 80 OMIM diseases
annotations when expected was just 40, which gave a P-value
of 6E-05. Remark that the 140 depleted genes showed no
significant enrichment in OMIM diseases annotations (39 vs. 41
expected, P = 0.59).
As best candidates for SLE association by rare variation,
we selected the set of 98 genes which simultaneously showed
Genomic Control and multi-testing corrected P < 0.05 in both
SKAT test and case-control burden test, with the purpose of
reducing the proportion of possible spurious associations. These
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FIGURE 2 | Numbers of variants were represented by dark columns: in the set
of 1,306,324 independent (r² < 0.1) polymorphic rare variants (MAF < 0.1),
189,893 (14.5%) were singletons (in the 8,277 individuals sample this means a
MAF = 0.006%), 676,621 (51.8%) were classified as “very rare-variants”
(0.006% <MAF < 0.1%), and 439,810 (33.7%) considered as a rare variation
in a “strict sense” (0.1% < MAF ≤ 1%); these numbers of variants were
represented by dark columns. Lighter columns represented the sums of alleles
of minor frequency in each of the 3 categories of rare variation, these 3
categories sum up 29,128,106 minor alleles: the 189,893 singletons
represented only 0.65% of minor alleles; the 676,621 the markers, which were
very rare variation, add up to 4,671,537 minor frequency alleles, it was the
16.04%; while the remaining markers, sum up to 24,266,676 of minor
frequency alleles representing the 83.33%.
are shown in Table 3. Some of these are discussed as excellent
candidates for the identification of individuals with particular
clinical phenotypes that may be directly targeted for sequencing.
ANNOVAR annotation of the independent mutations mapped
on these 98 genes are shown in Supplemental Table 5.
DISCUSSION
We have described a strategy to identify the association of rare
variation with a complex disease based on densely genotyped data
and stringent imputation. Our study provides a first list of genes
potentially involved in SLE through rare mutations that may have
an impact on the clinical presentation of the disease.
Although it could seem difficult to justify the role of non-
coding rare gene variation as causal, there are numerous
examples that support it. Efforts to identify risk alleles usually
are focused on exploring coding mutation by exome sequencing,
noting Pullabhatla et al. (25), as a recent example in SLE, but
analogous works for non-coding variants are scant. As examples
supporting the causative role of rare non-coding gene variation
in these complex phenotypes, it has been recently reported that
non-noding mutation affected plasma lipid traits in a founder
population (26), or in a more generalized perspective, it has
been demonstrated that rare variants contribute to large gene
TABLE 2 | Functional annotation of rare variation with and without r² filtering.
No r2 threshold r² < 0.1
Intronic 2,305,643 (85.09%) 1,253,088 (84.011%)
Intergenic 175,180 (6.465%) 101,187 (6.784%)
UTR3 46,322 (1.71%) 27,637 (1.853%)
Exonic 46,133 (1.70%) 30,053 (2.015%)
Downstream 26,690 (0.985%) 16,688 (1.119%)
Upstream 23,791 (0.878%) 15,095 (1.012%)
UTR5 9,872 (0.364%) 6,215 (0.417%)
Splicing 231 (0.009%) 171 (0.012%)
ncRNA intronic 68,381 (2.524%) 36,967 (2.478%)
ncRNA exonic 6,066 (0.224%) 3,600 (0.241%)
FIGURE 3 | Functional annotation of rare variation. Note that the percentages
of the different functional categories in rare variation with and without r² filtering
was similar, being the intronic the most abundant category, 85% of the total.
expression changes across tissues and provide an integrative
method for interpretation of rare variants effects (27).
It is important to point out that a significant test for aggregated
case-control burden test would indicate that in the set of
individuals forming the sample, the overall effect of the rare
variation on the gene goes in the same direction being either of
risk or protective. This feature of case-control burden analysis
helps to interpret the effect of rare variation on the phenotype,
which is measured by the overall OR values, OR > 1 or OR
<1, risk or protection, respectively. Mutations associated with
diseases were usually considered to be detrimental to health,
increasing the risk of disease. However, there are a growing
number of reported mutations shown to be protective, lowering
the risk of certain diseases and conditions (28–31). In this
context we can explain why the gene STAT4 associated to SLE
by common variation (32–45) and our 20th SKAT best-hit, failed
the burden test (Supplemental Tables 1, 4). There were two
sets of rare variation mapping on the gene with opposite join
effects and therefore reducing the power of the overall burden
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FIGURE 4 | Functional annotation of exonic rare variation. The exonic rare
variants represented only 2%, and more than 98% of these exonic mutations
were synonymous.
test. The same rationale could be applied to the other SLE
associated genes by common variation also detected as targets
by rare variation with SKAT but not by burden test in our
study (Supplemental Tables 1, 4): GTF2IRD1 (39, 42), DAB2
(41), NOTCH4 (37), CLEC16A (32, 42, 44), TNFSF4 (32, 40–46),
and C2 (36). The same can be argued for DOCK8 (ORburden.test
=2.33, P SKAT.corr = 0.03 and Pburden.test.corr = 0.204) the cause
of Hyper-IgE recurrent infection syndrome (HIES) autosomal
recessive by homozygous or compound heterozygous mutation
(OMIM #243700). Note that it has been reported a case of
DOCK8 deficiency caused by a truncating mutation, associated
with SLE (47).
Focusing on the best-hits which meet the criteria of
simultaneous significant association in both rare variation tests,
SKAT and burden test, we found some genes described
as associated with SLE by common variation such as
TMEM55B (46), SPATA8 (36), PRDM1 (32, 40, 42, 44, 48),
and HLA-DRB1 (36, 40, 42, 43, 45) (Table 3). Note IRF7 also
associated to SLE through common variants (32, 38, 44) had
association values through rare variation close to statistical
significance (PSKAT.corr = 0.082 and Pburden.test.corr = 0.036)
(Supplemental Table 4).
In this kind of studies it is usual to obtain lists of genes
with a difficult functional justification. However, in this case
we can relate many of the best hits in Table 3 directly to
immunological functions or with effects on other organs or
tissues affected by SLE, such as skin, central nervous system or
blood. For example our list contained C4A, PSKAT.corr = 0.014
and Pburden.test.corr = 0.0034, ORburden.test = 0.43 and
CI95%.burden.test = (0.23, 0.79), which was early related to
SLE through mutation [OMIM: 152700; (49)]. The zinc finger
E-box binding homeobox 1 gene, ZEB1, P SKAT.corr < 1.00E-
03 and Pburden.test.corr < 1.00E-03, ORenrich = 2.03 and CI
95%.enrich = (1.35, 3.05), acts as a transcriptional repressor
inhibiting interleukin-2 (IL-2) gene expression. Note that
IL-2 plays a critical role in immune tolerance, and insufficient
IL-2 production upon stimulation has been recognized in
SLE pathogenesis, particularly it has been described a new
epigenetic pathway in the control of IL-2 production in SLE
whereby low levels of miR-200a-3p accumulate the binding of
the ZEB1-CtBP2 complex to the IL-2 promoter and suppresses
IL-2 production (50). The role of CCR3 [P SKAT.corr = 0.00838
and Pburden.test.corr < 1.00E-03, ORburden.test = 3.74 and CI
95%.burden.test = (1.74, 8.02)] in inflammation is widely known
(OMIM ∗601268).
The protein encoded by CYP26B1, P SKAT.corr = 0.01
and Pburden.test.corr < 1.00E-03, ORburden.test = 1.7 and CI
95%.burden.test = (1.31, 2.21), functions as a critical regulator of all-
trans retinoic acid levels by the specific inactivation of all-trans
retinoic acid to hydroxylated forms. Mast cells (MCs) are known
to be regulators of inflammation. It has been reported that the
ATP-P2X7 pathway induces MCs activation and consequently
exacerbates inflammation. P2X7 expression onMCs was reduced
by fibroblasts in the skin. Cyp26b1 was highly expressed in skin
fibroblasts. Cyp26b1 inhibition resulted in upregulation of P2X7
on MCs and the presence of excessive amounts of retinoic acid
correlated with the increased expression of P2X7 on skin MCs
and consequent P2X7- and MC-dependent dermatitis (so-called
retinoid dermatitis) (51).
The protein encoded by TIGD7 belongs to the
“tigger subfamily of the pogo superfamily of DNA-
mediated transposons” in humans, P SKAT.corr = 0.0139
and Pburden.test.corr = 0.00179, ORburden.test = 3.04 and
CI95%.burden.test = (1.58, 5.86). The exact function of this gene
is not known, but it is very similar to CENPB considered a
major centromere auto-antigen recognized by sera from patients
with anti-cetromere-antibodies (ACA), which occur in some
autoimmune diseases, frequently in limited systemic scleroderma
and occasionally in its diffuse form (52, 53).
AQP8, P SKAT.corr = 0.0115 and Pburden.test.corr = 0.0063,
ORburden.test = 2.5 and CI 95%.burden.test = (1.42, 4.41). It has
been reported that efficient induction of B cell activation and
differentiation requires H2O2 fluxes across the plasmamembrane
for signal amplification. NADPH-oxidase 2 is the main source
of H2O2 and AQP8 is the transport facilitator across the
plasma membrane. AQP8 silencing inducible B lymphoma cells
responded poorly to TLR and BCR stimulation. Conversely
a silencing-resistant AQP8 rescued responsiveness (54). In
addition AQP8 was the major antibody target on human salivary
glands in patients with primary Sjögren’s syndrome (55).
It was known that SAMSN1 (=HACS1), P SKAT.corr = 0.012
and Pburden.test.corr = 0.0091, ORburden.test = 1.74 and
CI95%.burden.test = (1.21, 2.5), is up-regulated by B cell
activation signals and it participates in B cell activation and
differentiation (56).
MICB, P SKAT.corr = 0.0297 and Pburden.test.corr = 0.0062,
ORburden.test = 0.62 and CI 95%.burden.test = (0.45, 0.84), acts as
a stress-induced self-antigen that is recognized by gamma delta
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TABLE 3 | Best gene candidates for SLE association through rare variation in European ancestry population.
Gene Description NMUT nMAF.aff nMAF.ctr OR CI.95lo CI95up Pburden.test.corr PSKATcorr
ZEB1 Zinc finger E-box binding homeobox 1 74 1077 886 2.03 1.35 3.05 <1.00E-03 <1.00E-03
PRKAG3 Protein kinase, AMP-activated, gamma 3
non-catalytic subunit
4 53 95 0.55 0.39 0.78 <1.00E-03 <1.00E-03
COQ10B Coenzyme Q10 homolog B (S. cerevisiae) 3 11 38 0.25 0.13 0.5 <1.00E-03 <1.00E-03
MAD2L2 MAD2 mitotic arrest deficient-like 2 (yeast) 19 417 517 0.59 0.45 0.77 <1.00E-03 3.60E-03
TMEM69 Transmembrane protein 69 5 18 42 0.32 0.19 0.54 <1.00E-03 4.40E-03
KRTAP9-2 Keratin associated protein 9-2 3 4 14 0.16 0.05 0.5 <1.00E-03 6.20E-03
SERINC4 Serine incorporator 4 4 27 4 5.98 2.23 16.03 <1.00E-03 6.40E-03
CCR3 Chemokine (C-C motif) receptor 3 33 750 431 3.74 1.74 8.02 <1.00E-03 8.40E-03
CYP26B1 Cytochrome P450, family 26, subfamily B,
polypeptide 1
20 170 93 1.7 1.31 2.21 <1.00E-03 1.01E-02
TMEM106B Transmembrane protein 106B 24 103 244 0.56 0.38 0.82 <1.00E-03 1.77E-02
POU3F3 POU class 3 homeobox 3 2 66 33 3.47 1.46 8.22 <1.00E-03 2.41E-02
TIGD7 Tigger transposable element derived 7 14 109 55 3.04 1.58 5.86 1.80E-03 1.39E-02
KLF1 Kruppel-like factor 1 (erythroid) 3 90 48 3.01 1.46 6.2 1.80E-03 2.29E-02
PSMB8 Proteasome (prosome, macropain)
subunit, beta type, 8 (large multifunctional
peptidase 7)
30 439 490 0.64 0.48 0.84 1.80E-03 2.46E-02
MAPK15 Mitogen-activated protein kinase 15 6 55 78 0.57 0.4 0.82 1.80E-03 2.67E-02
AMACR Alpha-methylacyl-CoA racemase 20 347 261 1.64 1.17 2.29 1.80E-03 2.77E-02
UBE3A Ubiquitin protein ligase E3A 73 1164 1340 0.53 0.35 0.82 1.80E-03 3.93E-02
TRIM16L Tripartite motif containing 16-like 13 179 227 0.52 0.34 0.78 3.40E-03 <1.00E-03
CTSK Cathepsin K 3 23 41 0.26 0.1 0.68 3.40E-03 6.20E-03
HYPK Huntingtin interacting protein K 3 33 6 13.76 2.45 77.3 3.40E-03 8.30E-03
C4A Complement component 4A (Rodgers
blood group)
2 17 33 0.43 0.23 0.79 3.40E-03 1.40E-02
WNT10A Wingless-type MMTV integration site
family, member 10A
16 153 215 0.52 0.34 0.81 3.40E-03 1.57E-02
OR5B12 Olfactory receptor, family 5, subfamily B,
member 12
3 98 141 0.44 0.26 0.75 3.40E-03 1.78E-02
TAGLN3 Transgelin 3 27 225 275 0.58 0.4 0.84 3.40E-03 2.62E-02
PALM Paralemmin 65 653 740 0.52 0.34 0.79 3.40E-03 2.84E-02
SPACA1 Sperm acrosome associated 1 25 405 279 2.02 1.3 3.12 4.80E-03 6.10E-03
POPDC2 Popeye domain containing 2 36 444 309 2.47 1.39 4.4 4.80E-03 6.30E-03
ALG11 Asparagine-linked glycosylation 11,
alpha-1,2-mannosyltransferase homolog
(yeast)
10 60 91 0.59 0.42 0.83 4.80E-03 7.90E-03
SF3B4 Splicing factor 3b, subunit 4, 49kDa 3 58 88 0.39 0.2 0.78 4.80E-03 1.78E-02
DUSP7 Dual specificity phosphatase 7 4 32 12 8.12 2.03 32.54 4.80E-03 3.11E-02
MRGPRX4 MAS-related GPR, member X4 9 74 108 0.62 0.46 0.85 6.30E-03 7.50E-03
AQP8 Aquaporin 8 9 141 83 2.5 1.42 4.41 6.30E-03 1.15E-02
PI3 Peptidase inhibitor 3, skin-derived 2 20 4 3.85 1.29 11.5 6.30E-03 1.58E-02
FRS3 Fibroblast growth factor receptor
substrate 3
28 384 447 0.66 0.49 0.87 6.30E-03 2.78E-02
MICB MHC class I polypeptide-related
sequence B
47 1110 1166 0.62 0.45 0.84 6.30E-03 2.97E-02
GPBP1L1 GC-rich promoter binding protein 1-like 1 10 172 193 0.57 0.38 0.86 7.70E-03 <1.00E-03
DOLK Dolichol kinase 1 15 3 5.66 1.59 20.2 7.70E-03 9.90E-03
CSTA Cystatin A (stefin A) 23 266 200 2.26 1.28 3.97 7.70E-03 1.59E-02
KLHL31 Kelch-like 31 (Drosophila) 39 465 518 0.51 0.32 0.81 7.70E-03 1.61E-02
GPR26 G protein-coupled receptor 26 58 934 734 332 1.25 2.94 7.70E-03 1.65E-02
PRDM1 PR domain containing 1, with ZNF domain 26 278 332 0.62 0.44 0.86 7.70E-03 2.45E-02
COX17 COX17 cytochrome c oxidase assembly
homolog (S. cerevisiae)
32 398 280 2.13 1.31 3.46 7.70E-03 3.26E-02
(Continued)
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TABLE 3 | Continued
Gene Description NMUT nMAF.aff nMAF.ctr OR CI.95lo CI95up Pburden.test.corr PSKATcorr
SAMSN1 SAM domain, SH3 domain and nuclear
localization signals 1
129 1977 1622 1.74 1.21 2.5 9.10E-03 1.20E-02
ST8SIA2 ST8 alpha-N-acetyl-neuraminide
alpha-2,8-sialyltransferase 2
153 1583 1653 0.51 0.32 0.81 9.10E-03 1.75E-02
MAS1L MAS1 oncogene-like 12 141 171 0.52 0.32 0.83 9.10E-03 3.38E-02
TBCB Tubulin folding cofactor B 21 236 174 1.66 1.14 2.42 1.05E-02 <1.00E-03
FGR Gardner-Rasheed feline sarcoma viral
(v-fgr) oncogene homolog
6 154 93 1.97 1.17 3.3 1.05E-02 2.67E-02
WNK4 WNK lysine deficient protein kinase 4 5 161 116 2.06 1.25 3.41 1.05E-02 4.41E-02
MGAT5 Mannosyl (alpha-1,6-)-glycoprotein beta-
1,6-N-acetyl-glucosaminyltransferase
426 3961 3984 0.51 0.33 0.79 1.18E-02 2.64E-02
FEZF1 FEZ family zinc finger 1 3 49 74 0.37 0.18 0.79 1.18E-02 4.02E-02
ZNF461 Zinc finger protein 461 6 55 80 0.37 0.18 0.77 1.32E-02 2.34E-02
RAB25 RAB25, member RAS oncogene family 8 82 110 0.45 0.25 0.81 1.32E-02 3.94E-02
APLNR Apelin receptor 5 65 44 2.67 1.21 5.87 1.45E-02 1.07E-02
DUS1L Dihydrouridine synthase 1-like (S.
cerevisiae)
15 58 89 0.38 0.19 0.75 1.45E-02 2.60E-02
ASAH2 N-acylsphingosine amidohydrolase
(non-lysosomal ceramidase) 2
16 256 177 2.34 1.3 4.24 1.45E-02 2.76E-02
MRPS18B Mitochondrial ribosomal protein S18B 23 554 584 0.61 0.42 0.88 1.58E-02 1.76E-02
IL18RAP Interleukin 18 receptor accessory protein 22 278 213 1.62 1.12 2.34 1.58E-02 2.77E-02
BNIP2 BCL2/adenovirus E1B 19kDa interacting
protein 2
21 196 246 0.59 0.4 0.87 1.58E-02 2.93E-02
HAX1 HCLS1 associated protein X-1 2 47 17 2.04 1.16 3.61 1.58E-02 3.08E-02
ITFG3 Integrin alpha FG-GAP repeat containing 3 72 993 1076 0.5 0.3 0.8 1.58E-02 3.63E-02
ZNF99 Zinc finger protein 99 8 18 32 0.24 0.08 0.74 1.71E-02 1.51E-02
ZIK1 zinc finger protein interacting with K
protein 1 homolog (mouse)
15 173 116 1.9 1.18 3.06 1.71E-02 2.43E-02
PDZK1 PDZ domain containing 1 12 324 376 0.67 0.48 0.92 1.84E-02 2.43E-02
KRCC1 Lysine-rich coiled-coil 1 28 272 203 1.64 1.12 2.41 1.84E-02 4.45E-02
MAP1LC3C Microtubule-associated protein 1 light
chain 3 gamma
10 161 206 0.58 0.38 0.89 1.97E-02 2.24E-02
LRP4 Low density lipoprotein receptor-related
protein 4
1 12 2 5.28 1.16 23.99 1.97E-02 2.59E-02
OR52K2 Olfactory receptor, family 52, subfamily K,
member 2
14 158 196 0.57 0.36 0.88 1.97E-02 4.29E-02
GML Glycosylphosphatidylinositol anchored
molecule like protein
66 427 496 0.45 0.25 0.8 2.10E-02 1.30E-02
ARL4A ADP-ribosylation factor-like 4A 19 163 97 1.96 1.17 3.28 2.10E-02 3.85E-02
ANKRD39 Ankyrin repeat domain 39 3 36 55 0.58 0.38 0.9 2.22E-02 1.95E-02
HLA-DRB1 Major histocompatibility complex, class II,
DR beta 1
6 52 71 0.4 0.19 0.83 2.22E-02 2.51E-02
PNO1 Partner of NOB1 homolog (S. cerevisiae) 8 79 44 2.49 1.17 5.31 2.22E-02 3.94E-02
LCE2D Late cornified envelope 2D 3 45 49 0.38 0.17 0.86 2.22E-02 4.75E-02
ANAPC11 Anaphase promoting complex subunit 11 1 18 33 0.52 0.29 0.94 2.35E-02 4.86E-02
OR7A17 Olfactory receptor, family 7, subfamily A,
member 17
7 109 73 2.15 1.16 4.01 2.47E-02 3.93E-02
PTGDS Prostaglandin D2 synthase 21kDa (brain) 17 166 124 1.76 1.09 2.86 2.60E-02 1.01E-02
CCR1 Chemokine (C-C motif) receptor 1 8 149 89 1.81 1.09 3 2.72E-02 7.30E-03
CCDC12 Coiled-coil domain containing 12 29 380 272 1.98 1.13 3.47 2.97E-02 1.95E-02
REEP4 Receptor accessory protein 4 10 115 83 2.03 1.13 3.65 3.09E-02 3.22E-02
ZNF513 Zinc finger protein 513 3 18 29 0.51 0.28 0.94 3.09E-02 3.56E-02
SPATA8 Spermatogenesis associated 8 19 145 100 1.87 1.1 3.16 3.22E-02 3.60E-03
(Continued)
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TABLE 3 | Continued
Gene Description NMUT nMAF.aff nMAF.ctr OR CI.95lo CI95up Pburden.test.corr PSKATcorr
TAF15 TAF15 RNA polymerase II, TATA box
binding protein (TBP)-associated factor,
68kDa
49 439 346 1.89 1.12 3.19 3.22E-02 3.13E-02
POLR2I Polymerase (RNA) II (DNA directed)
polypeptide I, 14.5kDa
11 142 96 1.7 1.07 2.71 3.22E-02 3.84E-02
KCTD5 Potassium channel tetramerisation domain
containing 5
24 217 250 0.54 0.33 0.89 3.34E-02 1.59E-02
NKX2-5 NK2 homeobox 5 11 109 74 2.06 1.11 3.79 3.46E-02 3.23E-02
SCARA3 Scavenger receptor class A, member 3 69 593 469 1.68 1.09 2.59 3.46E-02 4.51E-02
EFNA4 Ephrin-A4 7 37 51 0.39 0.16 0.93 3.70E-02 2.52E-02
NRM Nurim (nuclear envelope membrane
protein)
11 229 233 0.65 0.44 0.95 3.82E-02 2.26E-02
TMEM55B Transmembrane protein 55B 8 72 45 1.57 1.06 2.31 3.94E-02 9.30E-03
MPL Myeloproliferative leukemia virus oncogene 15 83 44 2.48 1.16 5.31 4.06E-02 1.93E-02
PTGS2 Prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and
cyclooxygenase)
6 79 109 0.29 0.1 0.86 4.18E-02 3.61E-02
NT5DC1 5’-nucleotidase domain containing 1 87 736 558 2.43 1.09 5.41 4.18E-02 4.54E-02
MAFG v-maf musculoaponeurotic fibrosarcoma
oncogene homolog G (avian)
7 68 90 0.69 0.5 0.97 4.54E-02 1.11E-02
C5orf28 Chromosome 5 open reading frame 28 10 72 90 0.52 0.28 0.99 4.54E-02 3.22E-02
C8orf58 Chromosome 8 open reading frame 58 19 347 413 0.6 0.38 0.95 4.66E-02 3.85E-02
SNX5 Sorting nexin 5 63 490 374 1.99 1.08 3.64 4.77E-02 2.51E-02
PTER Phosphotriesterase related 98 846 716 2.11 1.06 4.2 4.89E-02 5.50E-03
ZNF708 Zinc finger protein 708 8 68 88 0.54 0.31 0.96 4.89E-02 1.69E-02
We selected the set of 98 genes which simultaneously showed Genomic Control and multi-testing corrected P-values < 0.05 in both SKAT test and Case-Control burden test (Case-
Control burden test helps to interpret the effect that the rare variation on each associated gene had on the phenotype, which is measured by the overall OR value and its 95%
confidence interval).
NMUT, number of mutations on tested gene; nMAF.aff, sum of minor frequency alleles in nMUT mutations in cases (4,212 cases); nMAF.ctr, sum of minor frequency alleles in nMUT
mutations in controls (4,065 controls); OR, case-control burden test Odds Ratio; CI.95lo, case-control burden test 95% Confidence Interval minor value; CI.95up: case-control burden
test 95% Confidence Interval major value; Pburden.test.corr , case-control burden test corrected P-value; and PSKAT.corr , SKAT corrected P-value.
T cells. MICB might play a role in both SLE and cutaneous
LE (CLE) in european population (57). In addition MICB
has been associated with susceptibility to SLE in Han Chinese
Population (58, 59).
CTSK, P SKAT.corr = 0.0062 and Pburden.test.corr = 0.0034,
ORburden.test = 0.28 and CI95%.burden.test = (0.1, 0.68), is highly
expressed by rheumatoid synovial fibroblasts (RSF) that are
activated by toll-like receptor signaling pathways in rheumatoid
arthritis and is known to play a key role in the degradation of
type Iand type II collagen. Thus, cathepsin K is implicated in
the degradation of bone and cartilage in RA (60). In addition
it has been suggested that CTSK is involved in development
of psoriasis-like skin lesions through TLR-dependent Th17
activation (61).
Autoinflammation, lipodystrophy, and dermatosis syndrome
(ALDD) can be caused by homozygous mutations in the
PSMB8 gene (OMIM: # 256040), P SKAT.corr = 0.0246
and Pburden.test.corr = 0.00179, ORburden.test = 0.64 and
CI 95%.burden.test = (0.48, 0.84). This autosomal recessive
systemic autoinflammatory disorder is characterized by
early childhood onset of annular erythematous plaques on
the face and extremities with subsequent development of
partial lipodystrophy and laboratory evidence of immune
dysregulation. More variable features include recurrent fever,
severe joint contractures, muscle weakness and atrophy,
hepatosplenomegaly, basal ganglia calcifications, and microcytic
anemia (62–64). This disorder encompasses Nakajo-Nishimura
syndrome (NKJO); joint In contractures, muscular atrophy,
microcytic anemia, and panniculitis-induced lipodystrophy
(JMP syndrome); and chronic atypical neutrophilic dermatosis
with lipodystrophy and elevated temperature syndrome
(CANDLE). Furthermore, mutations in PSMB8 and other
proteasome unit genes were shown to lead to an increased type I
interferon signature (65), a characteristic of SLE.
The roles of TRIM16L, P SKAT.corr = 0.0033 and
Pburden.test.corr < 1.00E-03, ORburden.test = 0.52 and
CI95%.burden.test = (0.34, 0.78), in immune response are
unknown, however it has been reported that in fish models
TRIM16L exerted negative regulation of the interferon immune
response against DNA virus infection (66). The early events that
facilitate viral persistence in chronic viral infections have been
linked to the activity of the immunoregulatory cytokine IL-10. It
has been reported that IL-10 induced the expression ofMGAT5, a
glycosyltransferase that enhances N-glycan branching on surface
glyco- proteins, P SKAT.corr = 0.0264 and Pburden.test.corr = 0.0118,
ORburden.test = 0.51 and CI 95%.burden.test = (0.33, 0.79). Increased
N-glycan branching on CD8+ T cells promoted the formation
of a galectin 3-mediated membrane lattice, which restricted
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the interaction of key glycoproteins, ultimately increasing the
antigenic threshold required for T cell activation allowing the
establishment of chronic infection (67).
The serine incorporator 4, SERINC4, P SKAT.corr = 0.0064
and Pburden.test.corr < 1.00E-03, ORburden.test = 5.98 and
CI95%.burden.test = (2.23, 16.03), incorporates amino acid serine
into membranes and facilitates the synthesis of two serine-
derived lipids, phosphatidylserine and sphingolipids (68).
Gene KLF1, PSKAT.corr = 0.00179 and Pburden.test.corr = 0.0229,
ORburden.test = 3.01 and CI95%.burden.test = (1.46, 6.20), encodes
a hematopoietic-specific transcription factor that induces high-
level expression of adult beta-globin and other erythroid genes.
Heterozygous loss-of-function mutations in this gene result
in the dominant In(Lu) blood phenotype (69). Compound
heterozygosity for KLF1 mutations is associated with microcytic
hypochromic anemia and increased fetal hemoglobin (70).
Mutations in KLF1 cause dyserythropoietic anemia congenital
type IV (OMIM: 613673).
TMEM106B [P SKAT.corr < 1.00E-03 and
Pburden.test.corr = 0.0177, ORburden.test = 0.56 and
CI95%.burden.test = (0.38, 0.82)] was associated with
frontotemporal dementia (71, 72). In addition TMEM106B
has been associated with inflammation, neuronal loss, and
cognitive deficits, even in the absence of known brain disease,
and their impact is highly selective for the frontal cerebral cortex
of older individuals (73).
Mutations affecting the gene ALG11 [PSKAT.corr = 0.0079
and Pburden.test.corr = 0.0048, ORburden.test = 0.56 and
CI95%.burden.test = (0.42, 0.83)] cause congenital disorder
of glycosylation 1P (CDG1P) [OMIM: 613661], a
multisystem disorder caused by a defect in glycoprotein
biosynthesis and characterized by under-glycosylated serum
glycoproteins. Congenital disorders of glycosylation result
in a wide variety of clinical features, such as defects in the
nervous system development, psychomotor retardation,
dysmorphic features, hypotonia, coagulation disorders, and
immunodeficiency (74, 75).
MAD2L2, PSKAT.corr < 0.001 and Pburden.test.corr = 0.0036,
ORburden.test = 0.59 and CI95%.burden.test = (0.45, 0.77), controls
DNA repair at telomeres and DNA breaks by inhibiting 5’
end resection (76). Note that a role for MAPK15 (=ERK8), P
SKAT.corr = 0.0018 and P enrich.corr = 0.0267, OR enrich = 0.57 and
CI 95%.enrich = (0.40,0.77), in the response to, or repair of, DNA
single strand breaks has been proposed (77), and it is annotated
as “positive regulation of telomerase activity,” biological process
(GO:0051973). MRGPRX4 (= MrgX4) [P SKAT.corr = 0.0063
and Pburden.test.corr = 0.00748, ORburden.test = 0.62 and
CI95%.burden.test = (0.46, 0.85)] is a Mas-related G-protein
coupled receptor X (MrgXs). It was described as an oncogene
in human colorectal cancers (78), however, it has recently been
linked to immunological functions. AG-30/5C is an angiogenic
host defense peptide (HDP) that activates various functions of
fibroblasts and endothelial cells, including cytokine/chemokine
production andwound healing. It has been shown that AG-30/5C
enhanced the production of cytokines/chemokines and facilitated
keratinocyte migration and proliferation mainly via MrgX3 and
MrgX4 receptors constitutively expressed in keratinocytes and
up-regulated upon stimulation with TLR ligands. AG-30/5C-
induced activation of keratinocytes was controlled by MAPK and
NF-κB pathways (79).
In addition other genes associated to human energy
metabolism and more specifically in the mitochondrion, as part
of the respiratory chain, the best hit associated to SLE by rare
variation was COQ10B, PSKAT.corr <0.001 and Pburden.test.corr
<0.001, ORburden.test = 0.25 and CI95%.burden.test = (0.13,
0.50). It encodes coenzyme Q, an essential component of
the electron transport chain. The copper metallochaperone
COX17, P SKAT.corr = 0.0077 and Pburden.test.corr = 0.0326,
ORburden.test = 2.13 and CI95%.burden.test = (1.31, 3.46), is
essential for the assembly and activation of the cytochrome
c oxidase complex (80), the terminal component of the
mitochondrial respiratory chain that catalyzes the electron
transfer from reduced cytochrome c to oxygen. Null mutations
in COX17 elicit a loss of cytochrome oxidase due to the
failure of the mutants to complete assembly of the complex
[OMIM: ∗604813]. It has been reported that SLE T-cells
have persistently hyperpolarized mitochondria associated with
increased mitochondrial mass, high levels of reactive oxygen
species (ROS) and low levels of ATP. These hyperpolarized
mitochondria resist the depolarization required for activation-
induced apoptosis and predispose T cells for necrosis, thus
stimulating inflammation in SLE (81, 82). Necrotic cell
lysates activate dendriticcells and might account for increased
interferon a production and inflammation in lupus patients
(83). Additionally, the mitochondrial ATP deficits also reduce
the macrophage energy that is needed to clear apoptotic
bodies (84). The mitochondrial transmembrane potential is
result of the respiratory electron transport chain that drives
the flow of electrons from NADH to molecular oxygen by
its last enzyme the cytochrome c oxidadase. Note that it
has been reported that COX17 is essential for activation of
cytochrome C oxidase (80) linking the COX17 function with the
SLE phenotype.
CONCLUSIONS
Here we present a set of 98 genes as good candidates for
association with SLE by mutation affecting a diversity of
functions in different organs and tissues. Considering that
complex phenotypes involves the intervention of multiple genes
associated by common variation, the same scheme could be
expected for genes associated by rare variation. Thus, each gene
or set of genes would influence in a small group of affected
carriers explaining the clinical heterogeneity or complexity
of this pathology. However, it is necessary to remark that
these results are preliminary and would need to be confirmed
by sequencing in the best candidate carriers in our sample
data set.
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